Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Formycon AG (FYB)

Xetra
Currency in EUR
48.35
-1.95(-3.88%)
Delayed Data
FYB Scorecard
Full Analysis
Analysts anticipate sales decline in the current year
Fair Value
Day's Range
48.2050.70
52 wk Range
37.6561.90
Key Statistics
Edit
Bid/Ask
48.30 / 48.65
Prev. Close
50.3
Open
50.7
Day's Range
48.2-50.7
52 wk Range
37.65-61.9
Volume
1.11K
Average Volume (3m)
4.84K
1-Year Change
-25.15%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FYB Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
86.56
Upside
+79.03%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year
Show more

Formycon AG Company Profile

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company’s pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn’s disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of immuno-oncology diseases; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Compare FYB to Peers and Sector

Metrics to compare
FYB
Peers
Sector
Relationship
P/E Ratio
13.9x−1.0x−0.7x
PEG Ratio
0.060.000.00
Price/Book
1.5x2.5x2.6x
Price / LTM Sales
14.6x8.2x3.2x
Upside (Analyst Target)
76.9%226.8%43.2%
Fair Value Upside
Unlock5.5%6.8%Unlock

Analysts' Recommendations

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 86.56

(+79.02% Upside)

FAQ

What Is the Formycon (FYB) Stock Price Today?

The Formycon stock price today is 48.35

What Stock Exchange Does Formycon Trade On?

Formycon is listed and trades on the Xetra stock exchange.

What Is the Stock Symbol for Formycon?

The stock symbol for Formycon is "FYB."

What Is the Formycon Market Cap?

As of today, Formycon market cap is 853.71M.

What is Formycon Earnings Per Share?

The Formycon EPS is 3.84.

What Is the Next Formycon Earnings Date?

Formycon will release its next earnings report on 23 Apr 2025.

From a Technical Analysis Perspective, Is FYB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.